Form 4 for CHRS Coherus Oncology, Inc.
Accepted 2023-04-04 00:00:00 ET · period of report 2023-03-31 · accession 0001140361-23-016457 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-04-04 | 2023-03-31 | CHRS | Vexler Vladimir | CSO | F - Tax | $6.84 | -16.3K | 116.4K | -12% | -$111.3K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-31 | F | D | 16,278 | $6.84 | 116,361 | D | — | — | (F1) Represents shares automatically withheld to pay related tax liability in connection with the vesting of restricted stock units in accordance with Rule 16b-3. (F2) Includes 1,316 shares acquired on May 13, 2022, pursuant to the Coherus BioSciences, Inc. Employee Stock Purchase Plan. |